Study Procedures
tumor, death
ADVERSE EVENTS, DISEASE PROGRESSION, TUMOR, DISEASE COURSE
All study observations were conducted at outpatient visits unless hospitalization was required for any reason. After providing informed consent, a screening period began within 28 days (4 weeks) before the first avapritinib dose. Safety monitoring was performed at the study center, and the tumor status of patients was evaluated by computed tomography (CT) or magnetic resonance imaging (MRI). Chest CT, and CT or MRI of the abdomen and pelvis, were performed at screening with intravenous contrast injection. All patients received radiological examination of the bodily areas containing the target and non-target lesions on day 1 of treatment cycle 3, and every two cycles thereafter. All patients in phase I and 2 participated in the end of treatment visit 14 (± 7) days after the last dose of the study drug. A safety follow-up was conducted by telephone 30 (± 7) days after the last dose of the study drug, or when the patient started another anti-tumor treatment, to determine the resolution/recovery status of adverse events. Subsequent follow-up was conducted every 3 months to evaluate the disease course, subsequent anti-tumor treatment, and survival until disease progression or death (or other withdrawal, including withdrawal of consent). 